Spyre Therapeutics to Participate in Upcoming Investor Conference
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on Inflammatory Bowel Disease (IBD) treatment, has announced its participation in the Stifel 2024 Virtual Immunology and Inflammation Summit. The company's management will engage in a fireside chat on Wednesday, September 18, 2024, at 12:00 p.m. Eastern time.
Spyre Therapeutics specializes in antibody engineering, rational therapeutic combinations, and precision medicine approaches to improve IBD treatment efficacy and convenience. Investors and interested parties can access a webcast replay of the fireside chat on the company's investor events website for 90 days following the event.
Spyre Therapeutics (NASDAQ: SYRE), una azienda biotecnologica in fase clinica focalizzata sul trattamento della malattia infiammatoria intestinale (IBD), ha annunciato la sua partecipazione al Summit Virtuale di Immunologia e Infiammatoria Stifel 2024. La direzione dell'azienda parteciperà a una chiacchierata informale mercoledì, 18 settembre 2024, alle 12:00 p.m. ora orientale.
Spyre Therapeutics si specializza nell'ingegneria degli anticorpi, nelle combinazioni terapeutiche razionali, e negli approcci di medicina di precisione per migliorare l'efficacia e la praticità del trattamento dell'IBD. Gli investitori e le parti interessate possono accedere a un replay della trasmissione web della chiacchierata informale sul sito web degli eventi per investitori dell'azienda per 90 giorni dopo l'evento.
Spyre Therapeutics (NASDAQ: SYRE), una compañía biotecnológica en etapa clínica centrada en el tratamiento de la enfermedad inflamatoria intestinal (IBD), ha anunciado su participación en el Summit Virtual de Inmunología e Inflamación Stifel 2024. La dirección de la compañía participará en una charla informal el miércoles 18 de septiembre de 2024, a las 12:00 p.m. hora del Este.
Spyre Therapeutics se especializa en ingeniería de anticuerpos, combinaciones terapéuticas racionales y enfoques de medicina de precisión para mejorar la eficacia y la comodidad en el tratamiento de la IBD. Los inversores y partes interesadas pueden acceder a una retransmisión web de la charla informal en el sitio web de eventos para inversores de la compañía por 90 días después del evento.
Spyre Therapeutics (NASDAQ: SYRE)는 염증성 장 질환 (IBD) 치료에 중점을 둔 임상 단계의 바이오테크 회사로, Stifel 2024 가상 면역학 및 염증 정상 회담에 참여한다고 발표했습니다. 회사 경영진은 2024년 9월 18일 수요일 오후 12시 (동부 표준시)에 파이어사이드 챗에 참여할 예정입니다.
Spyre Therapeutics는 IBD 치료의 효율성과 편의성을 향상시키기 위해 항체 공학, 합리적인 치료 조합, 정밀 의학 접근법에 전문성을 가지고 있습니다. 투자자 및 관심 있는 분들은 이벤트 후 90일 동안 회사의 투자자 이벤트 웹사이트에서 웹캐스트 재방송에 접근할 수 있습니다.
Spyre Therapeutics (NASDAQ: SYRE), une entreprise biopharmaceutique au stade clinique axée sur le traitement de la maladie inflammatoire de l'intestin (IBD), a annoncé sa participation au Sommet Virtuel d'Immunologie et d'Inflammation Stifel 2024. La direction de la société prendra part à un discussion informelle le mercredi 18 septembre 2024 à 12h00, heure de l'Est.
Spyre Therapeutics se spécialise dans l'ingénierie des anticorps, les combinaisons thérapeutiques rationnelles et les approches de médecine de précision pour améliorer l'efficacité et la commodité du traitement de l'IBD. Les investisseurs et les parties intéressées peuvent accéder à un rediffusion web de la discussion informelle sur le site web des événements pour investisseurs de l'entreprise pendant 90 jours après l'événement.
Spyre Therapeutics (NASDAQ: SYRE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung der Entzündlichen Darmerkrankung (IBD) konzentriert, hat seine Teilnahme am Stifel 2024 Virtuellen Immunologie- und Entzündungsgipfel angekündigt. Das Management des Unternehmens wird am Mittwoch, den 18. September 2024, um 12:00 Uhr Eastern Time an einem Fireside-Chat teilnehmen.
Spyre Therapeutics spezialisiert sich auf Antikörpertechnik, rationale therapeutische Kombinationen und präzisionsmedizinische Ansätze, um die Wirksamkeit und die Anwendung von IBD-Behandlungen zu verbessern. Investoren und Interessierte können für 90 Tage nach der Veranstaltung auf der Website für Investoren-Events des Unternehmens einen Webcast-Wiederholungslink des Fireside-Chats abrufen.
- None.
- None.
- Wednesday, September 18, 2024, at 12:00 p.m. Eastern time
A webcast replay will be available on the Spyre investor events website for 90 days following the event.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.
Follow Spyre Therapeutics on social media: @spyretx and LinkedIn
View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-participate-in-upcoming-investor-conference-302244312.html
SOURCE Spyre Therapeutics, Inc.
FAQ
When is Spyre Therapeutics (SYRE) participating in the Stifel 2024 Virtual Immunology and Inflammation Summit?
What is Spyre Therapeutics' (SYRE) focus in biotechnology?
How long will the webcast replay of Spyre Therapeutics' (SYRE) fireside chat be available?
What stock exchange is Spyre Therapeutics (SYRE) listed on?
